Stay updated with breaking news from Adalimumab. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
According to new research at ACR Convergence 2023, the American College of Rheumatology's (ACR) annual meeting, continuing tumor necrosis factor inhibitors during pregnancy is not associated with worse fetal or obstetric outcomes and may reduce the risk of severe maternal infections during pregnancy (Abstract #0477). ....
Panelists discuss reference biologic and biosimilar concentrations as well as the importance of citrate-free, less frequent injectable medications. ....